Sanjay Fernando, MD
Nephrology · New Britain, CTNPI 1457332157
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,062 of the $2,647 with a category attached, or 77.9%. 10 manufacturers reported payments, led by Baxter Healthcare at 44.8% of the total.
Across 32 payments — averaging $82.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$1K
- Mallinckrodt Hospital Products Inc.$291
- Novo Nordisk$246
- Amgen$244
- Otsuka America Pharmaceutical, Inc.$225
- Akebia Therapeutics Inc$155
- plus $301 from 4 others
What the payments were for
- Travel & lodging$57222%
- Food & beverage$2,06278%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 12 | $1,185 |
| Mallinckrodt Hospital Products Inc. | 2 | $291 |
| Novo Nordisk | 2 | $246 |
| Amgen | 2 | $244 |
| Otsuka America Pharmaceutical, Inc. | 2 | $225 |
| Akebia Therapeutics Inc | 3 | $155 |
| Calliditas Therapeutics US Inc. | 1 | $125 |
| Ascendis Pharma Endocrinology Inc | 1 | $94 |
| Lilly USA, LLC | 1 | $70 |
| Travere Therapeutics, Inc. | 6 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,647 in reported general payments places this provider in the 70th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 86 | $66,021 |
| XphozahTenapanor Hcl | 18 | $63,741 |
| FarxigaDapagliflozin Propanediol | 77 | $52,971 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $18,838 |
| Lanthanum Carbonate | 12 | $10,647 |
| Sevelamer Carbonate | 72 | $6,978 |
| Calcium Acetate | 83 | $2,900 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,547 |
| Bumetanide | 28 | $998 |
| Hydralazine Hcl | 52 | $949 |
| Calcitriol | 57 | $857 |
| Amlodipine Besylate | 95 | $857 |
| Carvedilol | 59 | $752 |
| Midodrine Hcl | 30 | $483 |
| Doxazosin Mesylate | 16 | $396 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New Britain
- Susan HalleyNew Britain$1K
- Zeynep EbciogluNew Britain$1K
- Adam GoldsteinNew Britain$1K
- Robert AlpernNew Haven$4.9M
- Ari GellerBloomfield$209K
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- James GavinTrumbull$103K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.